Osteosarcopenia revisited: from mechanisms to management
Abstract
Sarcopenia and osteoporosis are characterized by insufficient mass and function of skeletal muscle and bone, and often co-occur in older persons, a condition called osteosarcopenia. Loss of bone and skeletal muscle mass and function is driven by multiple risk factors that activate the hallmarks of aging. Recent genome-wide association studies in humans and animal models suggest pivotal roles for mitochondria, the nucleus, and nutrient anabolism, which are closely associated with the hallmarks of aging, as well as for osteokines and myokines, in the development of osteosarcopenia. Osteosarcopenia is associated with a higher risk of adverse outcomes, such as falls, fractures, depression, and frailty, and consequently with mortality. Diagnosis of osteosarcopenia involves various imaging techniques to assess BMD and skeletal muscle mass, as well as the assessments of physical performance or muscle function. Moreover, a comprehensive evaluation of medical history, medications, and laboratory data is important for identifying potential contributing factors and assessing risk. To manage and treat osteosarcopenia, a multimodal approach, such as exercise therapy, nutritional supplementation, and pharmacotherapies, is required. Future prospects include technological innovations such as artificial intelligence and the identification of novel biomarkers based on multi-omics analyses, which will help to enhance early detection of this condition. Emerging drugs that positively regulate bone and muscle mass are under development and are expected to contribute to individually optimized care for osteosarcopenia.
Related
- Acetabular revision surgery revisited: do changing indications influence bone defect management? A comprehensive review
- Prevalence of osteosarcopenia and associated factors among older Vietnamese outpatients: A cross-sectional study
- CT-Defined Osteosarcopenia Is Associated with Mortality in Metastatic Prostate Cancer: A Longitudinal Analysis of Opportunistic CT Imaging
- Interactions between chronic kidney disease and hyperuricemia in children: mechanisms, clinical manifestations and management updates
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
BibTeX
@article{sasako2026osteosarcopenia,
title = {{Osteosarcopenia revisited: from mechanisms to management}},
author = {Takayoshi Sasako and Miguel Germán Borda and Marc Sim and Gustavo Duque},
journal = {Journal of Bone and Mineral Research},
year = {2026},
month = aug,
doi = {10.1093/jbmr/zjag127},
url = {https://doi.org/10.1093/jbmr/zjag127},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Osteosarcopenia revisited: from mechanisms to management
AU - Takayoshi Sasako
AU - Miguel Germán Borda
AU - Marc Sim
AU - Gustavo Duque
PY - 2026
DA - 2026/08/22
JO - Journal of Bone and Mineral Research
DO - 10.1093/jbmr/zjag127
UR - https://doi.org/10.1093/jbmr/zjag127
AB - Sarcopenia and osteoporosis are characterized by insufficient mass and function of skeletal muscle and bone, and often co-occur in older persons, a condition called osteosarcopenia. Loss of bone and skeletal muscle mass and function is driven by multiple risk factors that activate the hallmarks of aging. Recent genome-wide association studies in humans and animal models suggest pivotal roles for mitochondria, the nucleus, and nutrient anabolism, which are closely associated with the hallmarks of aging, as well as for osteokines and myokines, in the development of osteosarcopenia. Osteosarcopenia is associated with a higher risk of adverse outcomes, such as falls, fractures, depression, and frailty, and consequently with mortality. Diagnosis of osteosarcopenia involves various imaging techniques to assess BMD and skeletal muscle mass, as well as the assessments of physical performance or muscle function. Moreover, a comprehensive evaluation of medical history, medications, and laboratory data is important for identifying potential contributing factors and assessing risk. To manage and treat osteosarcopenia, a multimodal approach, such as exercise therapy, nutritional supplementation, and pharmacotherapies, is required. Future prospects include technological innovations such as artificial intelligence and the identification of novel biomarkers based on multi-omics analyses, which will help to enhance early detection of this condition. Emerging drugs that positively regulate bone and muscle mass are under development and are expected to contribute to individually optimized care for osteosarcopenia.
SN - 0884-0431
SN - 1523-4681
ER -